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Background: The COVID-19 pandemic has caused radiotherapy resource pressures and led to increased
risks for lung cancer patients and healthcare staff. An international group of experts in lung cancer radio-
therapy established this practice recommendation pertaining to whether and how to adapt radiotherapy
for lung cancer in the COVID-19 pandemic.
Methods: For this ESTRO & ASTRO endorsed project, 32 experts in lung cancer radiotherapy contributed
to a modified Delphi consensus process. We assessed potential adaptations of radiotherapy in two pan-
demic scenarios. The first, an early pandemic scenario of risk mitigation, is characterized by an altered
risk–benefit ratio of radiotherapy for lung cancer patients due to their increased susceptibility for severe
COVID-19 infection, and minimization of patient travelling and exposure of radiotherapy staff. The sec-
ond, a later pandemic scenario, is characterized by reduced radiotherapy resources requiring patient
triage. Six common lung cancer cases were assessed for both scenarios: peripherally located stage I
NSCLC, locally advanced NSCLC, postoperative radiotherapy after resection of pN2 NSCLC, thoracic radio-
therapy and prophylactic cranial irradiation for limited stage SCLC and palliative thoracic radiotherapy
for stage IV NSCLC.
Results: In a risk-mitigation pandemic scenario, efforts should be made not to compromise the prognosis
of lung cancer patients by departing from guideline-recommended radiotherapy practice. In that same
scenario, postponement or interruption of radiotherapy treatment of COVID-19 positive patients is gen-
erally recommended to avoid exposure of cancer patients and staff to an increased risk of COVID-19 infec-
tion. In a severe pandemic scenario characterized by reduced resources, if patients must be triaged,
important factors for triage include potential for cure, relative benefit of radiation, life expectancy, andZurich,
9 pan-
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demic: An ESTRO-ASTRO consensus statement,performance status. Case-specific consensus recommendations regarding multimodality treatment
strategies and fractionation of radiotherapy are provided.
Conclusion: This joint ESTRO-ASTRO practice recommendation established pragmatic and balanced con-
sensus recommendations in common clinical scenarios of radiotherapy for lung cancer in order to
address the challenges of the COVID-19 pandemic.
 2020 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology xxx (2020) xxx–xxx This is
an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).After the outbreak of the coronavirus SARS-CoV-2 (COVID-19)
in Wuhan, China, in December 2019 [1], the disease rapidly
became a global pandemic. Infection rates peaked and began to
decline in some Asian countries by March 2020, but Europe and
the US are now among the most affected regions [2]. Most
COVID-19 infections are characterized by only mild symptoms of
fever and cough; however, there is a high risk of severe pulmonary
infection and death, in particular for the elderly and populations
with comorbidities such as diabetes, hypertension and cardiopul-
monary diseases [3,4]. Cancer patients have been reported to be
at increased risk of mortality [5]. Therefore, many countries have
implemented strategies to reduce the risk of spread, aiming to
slow-down or ‘‘flatten” the infection rate of the coronavirus and
to stay within the capacity of the healthcare services, especially
intensive care units [6].
The pandemic mitigation strategies of most countries also apply
to medical care in general and to oncology in particular, and
include reduction of elective services, a focus on remote visits
(e.g. telemedicine and video), and use of personal protective equip-
ment. However, most health authorities maintain emergency ser-
vices (e.g. for accidents) and services for diagnosis and treatment
of severe diseases such as cancer. These dramatic developments
related to COVID-19 are associated with challenges for the practice
of radiation oncology [7,8], especially for radiotherapy of lung can-
cer patients, who represent one of the highest-risk groups, with
high risks of death from both cancer and COVID-19 illness.
It may be challenging for radiation oncologists to continue to
follow accepted practice guidelines, given these limitations, and
delivering standard therapies may even become inappropriate.
There are two potential scenarios that may unfold, with different
radiation practice patterns [9].
In a first (early) pandemic scenario, sufficient resources are still
available to deliver radiation or multimodality treatment. This is
sometimes referred to as the ‘‘contingency standard of care” [10].
However, suppression strategies aiming to slow down the virus
spread may also impact the practice of lung cancer radiotherapy
due to: a) the need for suppression of the coronavirus and, there-
fore, the need to minimize the travel of patients [11] and exposure
of our radiotherapy staff [12]; b) an altered risk–benefit ratio of
radiotherapy for lung cancer patients due to their increased sus-
ceptibility for severe COVID-19 infection when repeatedly leaving
their home and traveling to radiotherapy treatment and simultane-
ously being treated with thoracic radiotherapy. For example, a
patient who contracts COVID-19 during a visit for radiation is at
a high risk of morbidity and death due to that visit. In this scenario
of the COVID-19 pandemic, standard-of-care practice of curative or
palliative radiotherapy for lung cancer might require adaptations
and lead to treatment recommendations that are outside current
guidelines [13].
In a second (later) pandemic scenario, radiotherapy resources
may not be available in sufficient quantity for treatment of all
patients. A severe shortage of radiotherapy resources may result
from sickness or home-quarantine of our department staffing. Ser-
vice or repair of radiotherapy software and hardware might be
restricted or unavailable by radiotherapy vendors. These issues
would require the allocation of resources and triage of patients
[14,15], in addition to the potential need to make changes to lungelka, A. Bezjak et al., Practice r
Radiotherapy and Oncology, htcancer radiotherapy prescriptions. This phase is sometimes
referred to as the ‘‘crisis standard of care” [10].
In this setting of the COVID-19 pandemic, hypofractionation is
an attractive treatment option, one that is actively being discussed
within the radiotherapy community on social media platforms
such as Twitter and theMednet. However, the results of such ad
hoc discussions do not address the needs of our radiotherapy com-
munity in an optimal way. Individual opinions may not be clini-
cally appropriate and might expose cancer patients to potential
harm from suboptimal radiotherapy practice. On the other end of
the spectrum, adoption of appropriate hypofractionation might
be low if that practice is outside of international guidelines and
not endorsed by recognized experts and professional societies,
yet such guidelines often take many months to develop.
In this practice recommendation, which is endorsed by the
European Society for Radiotherapy and Oncology (ESTRO) and the
American Society for Radiation Oncology (ASTRO), an international
group of experts in lung cancer radiotherapy aims to rapidly pro-
vide guidance about the potential need to adapt the practice and
fractionation of radiotherapy for lung cancer in the current
COVID-19 pandemic.Methods
On March 22nd, 32 experts in lung cancer radiotherapy were
invited to participate in this project, 16 European and 16 US/Cana-
dian experts. By March 24th, 97% had agreed, and a replacement
was found for the single invitee who was unavailable, to keep
the total at 32 with a balance between groups. All invited partici-
pants are co-authors of recent national and international lung can-
cer practice guidelines or principal investigators of lung cancer
clinical trials. A modified Delphi process was used to establish con-
sensus about whether and how to adapt radiotherapy for lung can-
cer in the COVID-19 pandemic [16]. Surveys were circulated to all
individual participants using the online survey tool SurveyMonkey.
All respondents agreed to participate in a rapid Delphi process,
with 24 h to complete each round and successive rounds starting
24 h after the closure of the previous round.
Two scenarios of the COVID-19 pandemic were assessed, both
of which were already occurring in some geographical regions:
d Early pandemic scenario 1 – risk mitigation: In this scenario, we
asked if respondents would recommend changes to standard
practice during the early phase, considering these challenges:
The altered risk–benefit ratio of radiotherapy for lung cancer
patients due to their increased susceptibility for severe
COVID-19 infection, and minimization of patient traveling and
exposure of our radiotherapy staff.
d Later pandemic scenario 2 – reduced radiotherapy resources: In
this scenario, we asked respondents to consider how their
above recommendations from scenario 1 would change if a lack
of radiotherapy resources prevented some patients at their cen-
tre from receiving radiation treatment.
Six common lung cancer cases were assessed for both pandemic
scenarios (Table 1). For all six, we assumed a patient with average /
standard characteristics for the lung cancer population. Theecommendations for lung cancer radiotherapy during the COVID-19 pan-
tps://doi.org/10.1016/j.radonc.2020.04.001
Table 1
The six lung cancer cases described, including the diagnosis and the presumed standard guideline-recommended therapy.
Case 1: Stage I NSCLC New diagnosis of stage I, inoperable, peripherally located NSCLC
Institutional standard fractionation of SBRT according to NCCN: 3–4 Fx total dose 45–54 Gy
Case 2: Stage III NSCLC Locally advanced stage IIIA (bulky N2) NSCLC
Standard fractionation of radiochemotherapy: 30–33 Fx over 6–6.5 weeks, total dose 60–66 Gy
Case 3: PORT NSCLC Resected N2 (multi-station and extra nodal spread) NSCLC
Standard fractionation of radiotherapy: 27 Fx over 5.5 weeks, total dose 54 Gy
Case 4: LS SCLC SCLC, limited stage
Standard fractionation of radiochemotherapy: 30 Fx over 3 weeks, BID, total dose 45 Gy, OR 33 Fx over 6.5 weeks, total dose 66 Gy
Case 5: PCI LS SCLC PCI for SCLC limited stage after good response to radiochemotherapy
Standard fractionation of radiotherapy: 10 Fx over 2 weeks, total dose 25 Gy
Case 6: palliative NSCLC Palliative metastatic NSCLC with failure after first-line chemo-IO combination and symptoms due to mediastinal/
hilar disease progression and severe cough and moderate dyspnea.
Standard fractionation of radiotherapy: 10 Fx over 2 weeks, total dose 30 Gy
M. Guckenberger et al. / Radiotherapy and Oncology xxx (xxxx) xxx 3standard treatment for each case was provided, consistent with
guideline-recommended radiotherapy according to current ver-
sions of the National Comprehensive Cancer Network (NCCN),
ESTRO, ASTRO and European Organization for Research and Treat-
ment of Cancer (EORTC) guidelines.
The questions for the first round of the Delphi process are
shown in Table 2. All responses were analyzed and consolidated
by two investigators (MG and DAP). A threshold of 66% for agree-
ment or disagreement was required for each item to reach consen-
sus and a threshold of 80% for strong consensus. For questions
voting on prioritizing the cases, the results of the vote are pre-
sented without necessarily achieving consensus. In the second
and third rounds, participants received the results and summary
of comments from prior rounds, and were asked to vote again on
items that had not reached 66% agreement. New questions were
constructed (by MG and DAP) in order to gain clarification or to
raise issues noted in the comments from participants. Following
the third round, any items still lacking consensus were not consid-
ered a recommendation, but some important issues raised by a
large minority of respondents are reflected below.Table 2
Questions in the first round of the Delphi process.
Early pandemic scenario 1 – risk mitigation
All cases Do you recommend that physicians change their radiotherapy p
(i.e. risks due to multiple visits, susceptibility of lung cancer pa
All cases Would you recommend postponing the initiation of treatment b
All cases Would you recommend hypofractionating beyond your usual fr
Case 1–3 Would your answers to questions #2 and #3 above change if th
Case 2 Would you recommend induction therapy in this case?
All cases If you recommended hypofractionation, what would be the maxi
service?
Specify the total dose, number of fractions, total treatment time
All cases If this patient was COVID-19 positive before starting treatment,
COVID-19 negative?
All cases If this patient became COVID-19 positive after starting treatment
and the test for COVID-19 negative?
Case 1 Case 1B: An operable patient with stage I NSCLC is referred to y
surgical capacity issues. Would you treat with SABR/SBRT?
Case 2 Would you recommend starting with induction chemotherapy t
Later pandemic scenario 2 – reduced radiotherapy resources
All cases How highly would you prioritize this patient’s treatment comp
All cases If there was a critical shortage of RT capacity, would you recom
All cases If you answered yes to the question above, what would be the
clinical service?
Specify the total dose, number of fractions, total treatment time
All cases In the setting of reduced RT capacity, if this patient was COVID-1
postpone the initiation of radiotherapy (in weeks)?
All cases In the setting of reduced RT capacity, if this patient became CO
until the patient becomes asymptomatic and the test for COVID
Overall Please rank the six cases in order of priority, starting with the h
Overall If you were to triage patients for treatment, in the setting of redu
gets treatment, in order of importance
Please cite this article as: M. Guckenberger, C. Belka, A. Bezjak et al., Practice r
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A total of three Delphi rounds were conducted. Surveys
remained open for 24 h and response rates were 29/32 (March
23rd, round 1), 31/32 (March 25th, round 2) and 30/32 (March
27th, round 3).Early phase of the COVID-19 pandemic: risk mitigation
Question: Would you recommend postponing the initiation of
treatment by 4–6 weeks?
In the early phase of the COVID-19 pandemic, decisions on
delay of treatment depended on the clinical case (Table 3). There
was a strong consensus not to postpone curative treatment for case
2 (stage III NSCLC), case 4 (LS SCLC) and case 6 (palliative NSCLC).
In contrast, there was a strong consensus to postpone treatment
for case 3 (PORT NSCLC) and a consensus to postpone for case 5
(PCI SCLC).
For case 1 (stage I NSCLC), answers on postponement were bal-
anced and we asked for factors influencing the decision whether orractice to address the challenges in this early phase of the COVID-19 pandemic?
tients to COVID-19 morbidity/mortality)
y 4–6 weeks?
actionation?
e tumor was mutation positive (EGFR or ALK) or PD-L1 positive (i.e. >50%)?
mum degree of hypofractionation you would propose to a patient in your clinical
, and provide any pertinent references if available.
would you postpone RT until the patient becomes asymptomatic and the test for
, would you recommend interrupting RT until the patient becomes asymptomatic
ou by a thoracic surgeon because timely access to surgery is not available due to
o postpone the start of radiation?
ared to all other cancer patients in your centre?
mend further hypofractionation beyond what you have described above?
maximum degree of hypofractionation you would propose to a patient in your
, and provide any pertinent references if available
9 positive before the start of treatment, what would be the maximum duration to
VID-19 positive after starting treatment, would you recommend interrupting RT
-19 negative?
ighest-priority case, in the setting of reduced resources
ced RT resources, please provide up to 5 factors that you would use to decide who
ecommendations for lung cancer radiotherapy during the COVID-19 pan-
tps://doi.org/10.1016/j.radonc.2020.04.001
Table 3
Recommendations regarding postponement of treatment.
Would you recommend postponing the initiation of treatment by 4–6 weeks?
Case Response
Case 1: stage I NSCLC Yes: 43%
No: 57%
Case 2: stage III NSCLC Yes: 4%
No: 96% (strong consensus)
Case 3: PORT NSCLC Yes: 82% (strong consensus)
No: 18%
Case 4: LS SCLC Yes: 11%
No: 89% (strong consensus)
Case 5: PCI SCLC Yes: 70% (consensus)
No: 30%
Case 6: Palliative NSCLC Yes: 4%
No: 96% (strong consensus)
4 ESTRO-ASTRO practice recommendations for lung cancer radiotherapy in COVID-19 pandemicnot to postpone. There was strong consensus that tumor growth
rate (87%) should be used in the decision-making process and some
support for these other factors (33–66%): patient preference, solid
component vs GGO, patient performance status, T1 vs T2, current
and future status of pandemic.
For case 5 (PCI SCLC) we asked about regular contrast-enhanced
cranial MRI follow up as an alternative to PCI: this strategy was
supported by 46% without reaching consensus.Question: Would you recommend hypofractionating beyond your
usual fractionation?
In the early phase of the COVID-19 pandemic, there was con-
sensus not to universally change radiotherapy practice to more
hypofractionated regimens (table 4). There was consensus or
strong consensus not to change to more hypofractionated
approaches in case 3 (PORT NSCLC), case 4 (LS SCLC) and case 5
(PCI SCLC). In contrast, there was strong consensus to change to
more hypofractionation in case 6 (palliative NSCLC).
If a decision was made for hypofractionation beyond standard
fractionations, there was strong consensus for using a single frac-
tion SBRT of 30–34 Gy in case 1 (stage I NSCLC). In case 6 (palliative
NSCLC), palliative regimens in 5 fractions, 2 fractions and a 1 frac-
tion all had similar support.
For case 2 (stage III NSCLC), we further differentiated fractiona-
tions based on whether the patient was treated with radiotherapy
only, with sequential radiochemotherapy or concomitant
radiochemotherapy. There was strong consensus that hypofrac-
tionated radiotherapy is appropriate in radiotherapy alone orTable 4
Fractionation recommendations.
Would you recommend hypofractionating beyond your usual fractionation?
Case Standard fractionations
Case 1: stage I NSCLC SBRT: 45–54 Gy in 3 Fx, 48 Gy in 4 fractions
Case 2: stage III NSCLC Radiochemotherapy: 60–66 Gy in
30–33 Fx over 6–6.5 weeks
Case 3: PORT NSCLC PORT: 50–60 Gy over 5–6 weeks
Case 4: LS SCLC Radiochemotherapy: 60–66 Gy in 30–33 Fx over
6–6.5 weeks, or 45 Gy in 30 Fx over 3 weeks
using BID fractions of 1.5 Gy
Case 5: PCI SCLC PCI: 25 Gy in 10 Fx over 2 weeks
Case 6: Palliative NSCLC 30 Gy in 10 Fx over 2 weeks
Please cite this article as: M. Guckenberger, C. Belka, A. Bezjak et al., Practice r
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against hypofractionation in concomitant radiochemotherapy
(Table 5). Various fractionations were considered as appropriate,
with total doses between 50 Gy and 66 Gy delivered in 15–30
fractions.
Question: An operable patient with stage I NSCLC is referred to you by
a thoracic surgeon because timely access to surgery is not available
due to surgical capacity issues. Would you treat with SBRT?
Surgical capacities might become especially at risk because of
the strong need for intensive care and ventilators in patients with
severe COVID-19 infection. We therefore addressed a situation
where an operable patient with stage I NSCLC is referred to radia-
tion oncology by a thoracic surgeon because timely access to sur-
gery is not available due to surgical capacity issues: it was asked
whether treatment with SBRT would be offered. There was a
100% consensus to offer SBRT.
Question: Which multi-modality strategies would you consider as
reasonable in order to address the challenges in this early phase of the
COVID-19 pandemic?
This question was asked for the curative stage III NSCLC (case 2)
only. It was explicitly described that the patient does not have any
contraindications against the guideline recommended standard-of-
care concomitant radiochemotherapy. Concurrent
radiochemotherapy achieved strong consensus as the preferred
treatment strategy. Radiotherapy alone, chemotherapy followed
by radiotherapy and chemotherapy followed by radiochemother-
apy were not considered as reasonable treatment strategies by
>33% of participants.
We also asked if respondents would recommend against any
standard concurrent chemotherapy agents (e.g. cisplatin-
etoposide, cisplatin-vinka alkaloid, cisplatin-pemetrexed,
carboplatin-paclitaxel, or carboplatin monotherapy), and there
was no consensus to recommend against any of these. The
carboplatin-paclitaxel regimen was chosen as a regimen of concern
most often (by 37% of respondents), potentially due to risks of
myelosuppression and/or pneumonitis.
Question: Would your multi-modality treatment strategy change if the
tumor was mutation positive (EGFR or ALK) or highly PD-L1 positive
(i.e. > 50%)? (Cases 1–3)
There was strong consensus (96%) not to change the treatment
strategy for case 1 (stage I NSCLC) and almost consensus (64%) for
case 3 (PORT NSCLC).Response Maximum degree of
hypofractionation supported
Yes: 50%
No: 50%
30–34 in 1 Fx [17]: 90% support if
choosing hypofractionation
(strong consensus)
Yes: 46%
No: 54%
Yes: 29%
No: 71%
(consensus)
Yes: 33%
No: 67%
(consensus)
Yes: 7%
No: 93% (strong consensus)
Yes: 89% (strong consensus)
No: 11%
Favored fractionations:
20 Gy in 5 Fx (30%) [18]
17 Gy in 2 Fx (37%) [19]
8–10 Gy in 1Fx (33%) [20]
ecommendations for lung cancer radiotherapy during the COVID-19 pan-
tps://doi.org/10.1016/j.radonc.2020.04.001
Table 6
Recommendations on delay or interruption of treatment in COVID-19 positive patients.
Patient case Time patient is diagnosed as COVID-19 positive Postpone or interrupt RT?
Case 1: Stage I NSCLC Start of Tx Yes: 96% (Strong consensus)
After start of Tx Yes: 54%
Case 2: Stage III NSCLC Start of Tx Yes: 100% (Strong consensus)
After start of Tx Yes: 57%
Case 3: PORT NSCLC Start of Tx Yes: 96% (Strong consensus)
After start of Tx Yes: 68% (Consensus)
Case 4: LS SCLC Start of Tx Yes: 89% (Strong consensus)
After start of Tx Yes: 48%
Case 5: PCI SCLC Start of Tx Yes: 93% (Strong consensus)
After start of Tx Yes: 67% (consensus)
Case 6: Palliative NSCLC Start of Tx Yes: 74% (Consensus)
After start of Tx Yes: 78% (Consensus)
Table 7
Recommendations regarding hypofractionation of treatment in the later phase of the
COVID-19 pandemic characterized by a lack of radiotherapy resources.
Case Maximum hypofractionation considered
as appropriate (66% threshold)
Case 1: stage I NSCLC 30–34 Gy in 1 Fx
Case 2: stage III NSCLC 55–60 Gy in 20 Fx
Case 3: PORT NSCLC Consensus against hypofractionation
Case 4: LS SCLC 40–45 Gy in 15 Fx
Case 5: PCI SCLC Consensus against hypofractionation
Case 6: Palliative NSCLC 8–10 Gy in 1 Fx
Table 5
Recommended hypofractionation regimens based on availability/use of concurrent and sequential radiochemotherapy, or radiotherapy alone.
Would you consider hypofractionated radiotherapy as appropriate?
Case 2 stage III NSCLC Response Maximum degree of hypofractionation supported
Radiotherapy only Yes: 97% (strong consensus)
No: 3%
60 Gy in 15 Fx (33%) [21,22]
60 Gy in 20 Fx (27%) [23]
60–66 Gy in 24–30 Fx (2.2–2.75 Gy/day) (23%) [24]
55 Gy in 20 Fx (13%) [25]
None (3%)
Sequential radiochemotherapy Yes: 97% (strong consensus)
No: 3%
60–66 Gy in 24–30 Fx (2.2–2.75 Gy/day) (27%) [24]
55 Gy in 20 Fx (27%) [25]
60 Gy in 15 Fx (23%) [21,22]
60 Gy in 20 Fx (20%) [23]
None (3%)
Concomitant radiochemotherapy Yes: 27%
No: 73% (consensus)
See footnote*
*Although there was consensus not to recommend hypofractionation, the respondents supportive of hypofractionation (n = 11) were asked which fractionation(s) they would
support, with multiple answers allowed. The favored options were 60–66 Gy in 22–30 Fx, given at 2.2–2.75 Gy/day, (75%) and 55 Gy in 20 Fx (63%).
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to postpone the start of radiotherapy for the populations described
in this question, although these are not yet evidence-based treat-
ment options. There was limited support but no consensus to con-
sider induction EGFR-targeting TKI for EGFR mutated NSCLC or
induction ALK-targeting TKI for NSCLC with ALK rearrangement
(38%); induction chemo-IO for cancers highly PD-L1 positive was
not supported (17%).
For case 3 (PORT NSCLC) we asked about EGFR/ALK targeting
TKIs and about immune-checkpoint inhibition (±chemotherapy)
as options to postpone radiotherapy or as alternatives to radiother-
apy (although these are not yet evidence-based treatment
options): none of these strategies was supported by >25% of the
participants.
Question: Handling of COVID-19 positive patients?
There was consensus in all cases to postpone initiation of radio-
therapy until the patient becomes asymptomatic and the test for
COVID-19 becomes negative (Table 6). When patients are diag-
nosed as COVID-19 positive during radiotherapy treatment, there
was consensus to interrupt radiotherapy until the patient becomes
asymptomatic and the test for COVID-19 is negative in cases 3, 5
and 6 whereas opinions were evenly split for the cases with cura-
tive radiotherapy at the time of primary diagnosis (cases 1, 2 and 4).
For case 2 (stage III NSCLC) and case 4 (LS SCLC) with longer
radiotherapy treatments, the following factors were described as
relevant in the decision-making process of whether or not to inter-
rupt radiotherapy in patients diagnosed as COVID-19 positive:Please cite this article as: M. Guckenberger, C. Belka, A. Bezjak et al., Practice r
demic: An ESTRO-ASTRO consensus statement, Radiotherapy and Oncology, htCOVID-19 related symptoms, symptoms of lung cancer, and infec-
tion with COVID-19 near the end of treatment.Later phase of the COVID-19 pandemic: lack of radiotherapy resources
and need for patient triage
For the later phase of the COVID-19 pandemic with potentially
reduced radiotherapy resources, we addressed the questions
whether further hypofractionation or postponement of radiother-
apy for COVID-19 positive patients would be considered as reason-
able and how to prioritize and triage patients. Results are
summarized in Table 7. For case 3 (PCI SCLC) there was strong con-
sensus (83%) for regular contrast-enhanced cranial MRI follow up
instead of PCI. Availability of MRI may, however, be limited during
a pandemic situation.ecommendations for lung cancer radiotherapy during the COVID-19 pan-
tps://doi.org/10.1016/j.radonc.2020.04.001
Table 8
Prioritization of lung cancer patients and factor for triaging of patients.
Prioritization of lung cancer patients Top 5 factors for triaging patients across
all radiotherapy cases
Rank Case* Relative Priority Compared All Other Types
Cancer Cases in Department**
1. Stage III NSCLC Very high/high
(71% consensus)
1. Potential for cure
2. LS-SCLC SCLC Very high/high
(78% consensus)
2. Relative benefit of RT vs. other treatment options
3. Stage I NSCLC High/average
(near consensus: 65%)
3. Active COVID-19 infection (absence thereof)
4. Palliative NSCLC No consensus. Widely dispersed responses. 4. Life expectancy
5. PORT NSCLC Low/very low (68% consensus) 5. Performance Status
6. SCLC PCI Low/very low (81% consensus)
*The six cases were ranked, with 6 points given for a #1 ranking, 5 points for #2, etc, and the average number of points was determined. The average scores, in order of
ranking as listed in the table, were 5.2, 4.9, 4.1, 3.0, 2.1 and 1.7, respectively.
**Respondents were asked to prioritize each case as very high, high, average, low, or very low, corresponding to quintiles of priority (e.g. very high = top 20%, very
low = bottom 20%), compared to all types of cancers treated in their department. Adjacent categories were combined to determine consensus.
6 ESTRO-ASTRO practice recommendations for lung cancer radiotherapy in COVID-19 pandemicRegarding postponement or interruption of treatment for
COVID-19 positive patients during scenario 2, since the consensus
in Scenario 1 was to postpone and interrupt in all situations, it was
concluded that treatment would be postponed/interrupted until
the patient recovers and is COVID-19 negative in Scenario 2 as
well, since it is a more extreme example.
Prioritization of cases and triage of patients
Table 8 shows the ranking of cases based on relative priority,
their perceived priority relative to all other types of cancer cases,
and the top 5 factors recommended in order to triage patients in
a setting where not all patients can receive radiotherapy due to
capacity shortages.
Discussion
This Delphi process was able to achieve consensus in many
important aspects of lung cancer radiotherapy in the current
COVID-19 pandemic. A total of 32 international experts in lung
cancer radiotherapy completed 3 rounds of a consensus-building
process and addressed six common lung cancer cases within the
context of two different scenarios of the COVID-19 pandemic.
Beyond detailed recommendations shown above, the following
three take-home messages should be considered in lung cancer
radiotherapy.
First, in a risk-mitigation pandemic scenario where radiother-
apy resources remain available, efforts should be made to not com-
promise the prognosis of lung cancer patients by departing from
guideline-recommended radiotherapy practice. Second, in that
same scenario, postponement or interruption of radiotherapy
treatment of COVID-19 positive patients should be considered to
avoid exposure of cancer patients and staff to an increased risk
of COVID-19 infection. Third, in a severe pandemic scenario char-
acterized by reduced resources, if patients must be triaged, impor-
tant factors included potential for cure, relative benefit of
radiation, life expectancy, and performance status.
This joint ESTRO-ASTRO practice recommendation aims to pro-
vide rapid, pragmatic and balanced guidance in common clinical
scenarios of radiotherapy for lung cancer. Practitioners must use
their clinical judgement when considering how these consensus
statements apply to their individual clinical practice. These con-
sensus statements are not absolute clinical practice recommenda-
tions. Clinical decisions should take into account all clinical factors,
and in some settings the consensus recommendations may not be
appropriate. The decision-making process will be influenced by
various stakeholders (governments, health care authorities, hospi-Please cite this article as: M. Guckenberger, C. Belka, A. Bezjak et al., Practice r
demic: An ESTRO-ASTRO consensus statement, Radiotherapy and Oncology, httal and university administration), will be restricted by logistical
and financial aspects, will need to follow the appropriate legal
frameworks, and will need to be put into political and cultural con-
text. The ability to implement hypofractionation may depend on
departmental resources available (e.g. physicist).
This ESTRO-ASTRO practice recommendation used methodolo-
gies that are established quality indicators for regular consensus
and guideline processes [26]: the practice recommendation was
officially endorsed by the ESTRO and ASTRO societies, a sufficiently
large group of international experts in lung cancer radiotherapy
contributed to this recommendation, the modified Delphi process
started with open questions aiming to comprehensively collect
the knowledge and opinions of all participants and consensus
was established by follow-up rounds of feedback and voting. A sys-
tematic review was not part of the practice recommendation due
to time constraints, and especially due to a lack of evidence for
pandemic situations.
All co-authors therefore encourage practitioners to consider the
results of this ESTRO-ASTRO practice recommendation on whether
and how to adapt radiotherapy for lung cancer to the COVID-19
pandemic. Finally, we want to express our gratitude to all col-
leagues of all professions and disciplines who continue delivering
optimal cancer care in serious situations such as now – take care
of yourselves as well as your patients.ESTRO Disclaimer
ESTRO cannot endorse all statements or opinions made on the
guidelines. Regardless of the vast professional knowledge and sci-
entific expertise in the field of radiation oncology that ESTRO pos-
sesses, the Society cannot inspect all information to determine the
truthfulness, accuracy, reliability, completeness or relevancy
thereof. Under no circumstances will ESTRO be held liable for
any decision taken or acted upon as a result of reliance on the con-
tent of the guidelines. The component information of the guideli-
nes is not intended or implied to be a substitute for professional
medical advice or medical care. The advice of a medical profes-
sional should always be sought prior to commencing any form of
medical treatment. To this end, all component information con-
tained within the guidelines is done so for solely educational and
scientific purposes. ESTRO and all of its staff, agents and members
disclaim any and all warranties and representations with regards
to the information contained on the guidelines. This includes any
implied warranties and conditions that may be derived from the
aforementioned guidelines.ecommendations for lung cancer radiotherapy during the COVID-19 pan-
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Disclaimer and Adherence: American Society for Radiation
Oncology (ASTRO) guidelines present scientific, health, and safety
information and may reflect scientific or medical opinion. They
are available to ASTRO members and the public for educational
and informational purposes only. Commercial use of any content
in this guideline without the prior written consent of ASTRO is
strictly prohibited. Adherence to this guideline does not ensure
successful treatment in every situation. This guideline should not
be deemed inclusive of all proper methods of care or exclusive of
other methods reasonably directed to obtaining the same results.
The physician must make the ultimate judgment regarding therapy
considering all circumstances presented by the patient. ASTRO
assumes no liability for the information, conclusions, and findings
contained in its guidelines. This guideline cannot be assumed to
apply to the use of these interventions performed in the context
of clinical trials. This guideline is based on information available
at the time the task force conducted its research and discussions
on this topic. There may be new developments that are not
reflected in this guideline and that may, over time, be a basis for
ASTRO to revisit and update the guideline.Conflict of interest disclosures
A. Bezjak: AstraZeneca advisory board.
J. Bradley: AstraZeneca Scientific Advisory Board; Mevion Med-
ical Systems Scientific Advisory Board; Genentech Scientific Advi-
sory Board.
M. Daly: Research funding from EMD Serono and Genentech,
Boston Scientific Advisory Board, Triptych Health Partners
consulting.
R. Dziadziuszko: AstraZeneca, Pfizer, Roche, Seattle Genetics,
Takeda Advisory Boards.
C. Faivre-Finn: research funding from AstraZeneca and Elekta
and Astra Zeneca Advisory Boards.
M. Guckenberger: research funding from AstraZeneca.
K. Higgins: Astra Zenenca Advisory Board/Consultant, Genetech
Advisory Board, Varian Consultant. Research Funding RefleXion
Medical.
C. Le Pechoux: Participation in Astra Zeneca, Nanobiotix and
Roche Advisory Boards, Participation in educational meetings
Amgen, Astra Zeneca, Lilly, Medscape, PrimeOncology.
Y. Lievens: personal fees from AstraZeneca and RaySearch.
U. Ricardo: Astra Zeneca Advisory Board.
A. Rimner: Research funding from Varian Medical Systems,
Boehringer Ingelheim, Pfizer, AstraZeneca, Merck; Personal fees
from: AstraZeneca, Merck, Research to Practice, Cybrexa, More
Health.
S. Schild: UpToDate.
S. Senan: consulting/advisory fees from AstraZeneca, Merck,
Celgene, and departmental research funding from ViewRay Inc.,
Varian Medical Systems and AstraZeneca.
M. Stuschke: research funding from AstraZeneca.
S. Yom: research funding from Genentech, Merck, Bristol-Myers
Squibb, BioMimetix;
The other authors declare no conflicts of interest.Please cite this article as: M. Guckenberger, C. Belka, A. Bezjak et al., Practice r
demic: An ESTRO-ASTRO consensus statement, Radiotherapy and Oncology, htReferences
[1] Li Q et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-
infected pneumonia. N Engl J Med 2020.
[2] Rosenbaum L. Facing Covid-19 in Italy — Ethics, Logistics, and Therapeutics on
the Epidemic’s Front Line. N Engl J Med 2020.
[3] Guan W et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N
Engl J Med 2020.
[4] Zhou F et al. Clinical course and risk factors for mortality of adult inpatients
with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet
2020.
[5] Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for cancer patients. Lancet
Oncol 2020.
[6] Ferguson N.M. et al. Impact of non-pharmaceutical interventions (NPIs) to
reduce COVID-19 mortality and healthcare demand 2020:20.
[7] Filippi AR, Russi E, Magrini SM, Corvò R. COVID-19 outbreak in northern Italy:
first practical indications for radiotherapy departments. Int J Radiat Oncol Biol
Phys 2020.
[8] Krengli M, Ferrara E, Mastroleo F, Brambilla M, Ricardi U. Running a Radiation
Oncology Department at the time of coronavirus: an Italian experience. Adv
Radiat Oncol 2020.
[9] Zhao Z, Bai H, Duan JC, Wang J. Individualized treatment recommendations for
lung cancer patients at different stages of treatment during the outbreak of
2019 novel coronavirus disease epidemic. Zhonghua Zhong Liu Za Zhi 2020;42:
E007.
[10] Stroud C. Institute of Medicine (U.S.) & Forum on Medical and Public Health
Preparedness for Catastrophic Events. Crisis standards of care: summary of a
workshop series, National Academies Press: 2010.
[11] Chinazzi M et al. The effect of travel restrictions on the spread of the 2019
novel coronavirus (COVID-19) outbreak. Science 2020. https://doi.org/
10.1126/science.aba9757.
[12] Lancet T. COVID-19: protecting health-care workers. The Lancet
2020;395:922.
[13] Francesco C, Pettke A, Michele B, Fabio P, Helleday T. Managing COVID-19 in
the oncology clinic and avoiding the distraction effect. Ann Oncol 2020;
S0923753420363730. https://doi.org/10.1016/j.annonc.2020.03.286.
[14] Christian MD. Triage Crit Care Clin 2019;35:575–89.
[15] Emanuel EJ et al. Fair allocation of scarce medical resources in the time of
Covid-19. N Engl J Med 2020.
[16] Hsu C-C, Sandford BA. The Delphi Technique: Making Sense of Consensus. 12,
8.
[17] Videtic GM et al. Long-term follow-up on NRG oncology RTOG 0915 (NCCTG
N0927): A randomized phase 2 study comparing 2 stereotactic body radiation
therapy schedules for medically inoperable patients with stage I peripheral
non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2019;103:1077–84.
[18] Bezjak A et al. Randomized phase III trial of single versus fractionated thoracic
radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J
Radiat Oncol 2002;54:719–28.
[19] Medical Research Council Lung Cancer Working Party et al. Randomized trial
of palliative two-fraction versus more intensive 13-fraction radiotherapy for
patients with inoperable non-small cell lung cancer and good performance
status. Clin Oncol 1996;8:167–75.
[20] Medical A. Research Council (MRC) randomised trial of palliative radiotherapy
with two fractions or a single fraction in patients with inoperable non-small-
cell lung cancer (NSCLC) and poor performance status. Medical Research
Council Lung Cancer Working Party. Br J Cancer 1992;65:934–41.
[21] Westover KD et al. Precision hypofractionated radiation therapy in poor
performing patients with non-small cell lung cancer: phase 1 dose escalation
trial. Int J Radiat Oncol 2015;93:72–81.
[22] Iyengar P et al. A phase III randomized study of image guided conventional (60
Gy/30 fx) versus accelerated, hypofractionated (60 Gy/15 fx) radiation for poor
performance status stage II and III NSCLC patients—an interim analysis. Int J
Radiat Oncol Biol Phys 2016;96:E451.
[23] Osti MF et al. Image guided hypofractionated 3-dimensional radiation therapy
in patients with inoperable advanced stage non-small cell lung cancer. Int J
Radiat Oncol 2013;85:e157–63.
[24] Belderbos J et al. Randomised trial of sequential versus concurrent chemo-
radiotherapy in patients with inoperable non-small cell lung cancer (EORTC
08972–22973). Eur J Cancer 2007;43:114–21.
[25] Maguire J et al. SOCCAR: a randomised phase II trial comparing sequential
versus concurrent chemotherapy and radical hypofractionated radiotherapy in
patients with inoperable stage III Non-Small Cell Lung Cancer and good
performance status. Eur J Cancer 2014;50:2939–49.
[26] Kötter T, Blozik E, Scherer M. Methods for the guideline-based development of
quality indicators–a systematic review. Implement Sci 2012;7:21.ecommendations for lung cancer radiotherapy during the COVID-19 pan-
tps://doi.org/10.1016/j.radonc.2020.04.001
